Table 1.
Demographic and Clinical Data
| Adults | Pediatric | P Value | |||
|---|---|---|---|---|---|
| CPD (n=19) | COVID-ARDS (n=13) | MIS-C (n=16) | Non MIS-C (n=31) | ||
| Demographics | |||||
| Age, years, median (range) | 45 (28-69) | 62 (19-84) | 11 (4-17) | 11 (3-18) | |
| Sex, male (%) | 10 (53%) | 11 (85%) | 7 (44%) | 17 (55%) | |
| Body Mass Index, median (IQR) | na | 33.8 (28.4-36.1) | 19.1 (17.3-25.5) | 19.3 (16.9-22.3) | |
| Race or Ethnic Group (%)a | |||||
| Hispanic or Latino | 1 (5%) | 4 (31%) | 4 (25%) | 13 (42%) | |
| Black or African American | 0 | 3 (23%) | 7 (44%) | 4 (13%) | |
| White | 10 (53%) | 2 (15%) | 7 (44%) | 15 (48%) | |
| Asian | 6 (32%) | 0 | 0 | 0 | |
| Pacific Islander | 2 (11%) | 0 | 0 | 0 | |
| Other or Unknown | 1 (5%) | 5 (38%) | 1 (6%) | 7 (23%) | |
| Clinical Characteristics | |||||
| SARS-CoV-2 PCR Positive (%)b | na | 13 (100%) | 8 (50%) | 22 (71%) | |
| Asymptomatic (%) | na | 0 | 0 | 15 (48%) | |
| Days Post Symptom Onset, median (IQR)c | 24 (19–37) | 16 (14–21) | 6 (4–7) | 29 (17–44)d | |
| SOFA Scoree, median (IQR)f | na | 11 (9.5–14) | 4 (3–7) | na | |
| Acute Respiratory Distress Syndrome (%) | na | 13 (100%) | 1 (6%) | 1 (3%) | |
| In-hospital Mortality (%)g | na | 6 (46%) | 0 (0%) | 0 (0%) | |
| Laboratory Results, median (IQR)f,h,i | |||||
| Absolute Neutrophil Count, x10(3)/μL | na | 14.7 (9.1-25.2) | 8.9 (7.2-16.4) | 5.0 (3.2-8.0) | 0.0005 |
| Absolute Lymphocyte Count x10(3)/μL | na | 0.9 (0.7-1.4) | 0.8 (0.4-1.5) | 2.0 (1.3-2.8) | 0.0001 |
| Albumin, g/dL | na | 3.4 (2.8-3.5) | 3.4 (2.6-4.2) | 4.6 (4.3-4.9) | 2.6x10−7 |
| D-dimer, μg/mL | na | 7.9(1.7-16.1) | 3.1 (1.7-4.3) | na | 0.07 |
| Ferritin, ng/mL | na | 1933 (971-2693) | 521 (298-998) | na | 0.002 |
| High Sensitivity CRP, mg/L | na | 128 (69-207) | 214 (47-300) | na | 0.56 |
| Interleukin-6, pg/mL | na | 82 (56-315) | 219 (54-315) | na | 0.63 |
| Lactate Dehydrogenase, U/L | na | 777 (638-1379) | 268 (229-373) | na | 0.0003 |
| Procalcitonin, ng/mL | na | 0.4 (0.3-2.0 | 8.8 (2.1-61.6) | na | 0.002 |
| Troponin T, high sensitivity, ng/L | na | 24 (16-59) | 20 (6-92) | na | 0.85 |
Abbreviations: CPD, convalescent plasma donor; ARDS, Acute Respiratory Distress Syndrome; MIS-C Multisystem Inflammatory Syndrome in Children; SOFA, Sequential Organ Failure Assessment; IQR, Interquartile Range; PCR, Polymerase chain reaction; CRP, C-Reactive Protein
Individuals included in all groups for which they identified
Indeterminate tests were treated as positive
Respiratory symptoms/COVID-19 symptoms for CPD/ARDS groups and symptoms of MIS-C for MIS-C group
Subjective reporting of days post symptom onset for those presenting with symptoms or total days after confirmed COVID-19 exposure (reportable data available for n=16 subjects)
Pediatric and Adult specific scoring applied to groups; not meant for direct comparison
Day of admission for MIS-C, day of intubation for COVID-ARDS, day of PCR or Serology sample testing for Non MIS-C
30 Day In-hospital mortality, 4 patients remain hospitalized
Values above upper limit entered as; D-Dimer (20 mg/mL), Ferritin (100,000 ng/mL), CRP (200 mg/L), Interleukin-6 (315 pg/mL), Lactate Dehydrogenase (5000 U/L)
Statistical testing for Absolute Neutrophil Count, Absolute Lymphocyte Count and Albumin done via Kruskal-Wallis one-way analysis of variance. Statistical testing for all other laboratory results done by two-tailed Mann-Whitney test. P values were calculated to 4 decimal places. Absolute Neutrophil Count and Absolute Lymphocyte Count; n=13 COVID-ARDS, n=16 MIS-C, n=27 Non MIS-C. Albumin; n=13 COVID-ARDS, n=16 MIS-C, n=15 Non MIS-C. D-dimer and Ferritin; n=13 COVID-ARDS, n=16 MIS-C. For High Sensitivity CRP; n=12 COVID-ARDS, n=16 MIS-C. Interleukin-6 and Troponin; n=11 COVID-ARDS, n=16 MIS-C. Lactate Dehydrogenase; n=12 COVID-ARDS, n=15 MIS-C. Procalcitonin; n= 13 COVID-ARDS, n=12 MIS-C.